CAY10505 is a potent PI3Kγ inhibitor with an IC50 of 30 nM. Phosphoinositide 3-kinase γ (PI3Kγ) is expressed primarily in hematopoietic cells and plays several important roles in immunity. CAY10505 also prevents other α, β, and δ isoforms with IC50 of 0.94, 20, and 20 μM, respectively. CAY10505 significantly inhibits only the unrelated casein kinase 2 (CK2, IC50 = 20 nM). CAY10505 also suppress the phosphorylation of the PI3K substrate PKB/Akt in murine macrophages (IC50 = 228 nM). Oral administration of CAY10505 decreases neutrophil recruitment in mice to an extent that is comparable to that observed in PI3Kγ-deficient mice.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 50 mg/mL|
|Related PI3K Products|
GSK2292767 is a potent and selective PI3Kδ inhibitor.
Bimiralisib (PQR309) is an orally bioavailable inhibitor of PI3K and mTOR, with potential antineoplastic activity.
PIK-III (also known as VPS34-IN2) is a potent and selective inhibitor of VPS34 enzymatic activity, with IC50s of 18 nM and 1.2 μM for VPS34 and PI(3)Kδ, respectively.
LY3023414 is a selective ATP-competitive inhibitor of PI3Kα and mTOR, DNA-PK, and other class I PI3K family members.
SAR405 is a PIK3C3/Vps34 inhibitor with an IC50 of 1.2 nM. SAR405 also is a proximal inhibitor of the autophagy machinery.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.